

TEST THERAPADD 2A

Evaluation of new compounds for the treatment of moderate cocaine use disorder in rodents

Background

Among illicit substances, cocaine is the one with the highest societal cost. The majority of the estimated 14 million cocaine users worldwide users are affected by mild and moderate cocaine use disorders which compromise health and daily life.

Despite a tremendous amount of research devoted to understanding cocaine use disorders, the therapeutic approaches developed so far remain limited in number and efficacy.

Assay principle

Anti-abuse compounds should decrease motivation for cocaine, improve control on drug intake and relapse in withdrawn users.

Assay Information

Biological models	Male rats
Methods	Cocaine intravenous self-administration
Readouts	Ability to : <ul style="list-style-type: none"> • decrease motivation for cocaine • decrease escalation during extended access to cocaine • decrease cocaine- or cue-induced relapse
Standard reference	CB1 antagonist
Turn around time	12 weeks per test

Person in charge

Dr. Véronique Deroche-Gamonet, PhD

Contact : [optopath « at » u-bordeaux.fr](mailto:optopath@u-bordeaux.fr)